Perrigo Company PLC officially reaches the finish line on becoming a manufacturer entirely focused on consumer health product with the closing of its $1.55bn deal to divest its generic Rx product business to Altaris Capital Partners LLC.
"Closing this transaction was another important milestone for Perrigo's transformation. We are now a leading pure-play global consumer self-care company...